Comparison of acquisition schemes for hyperpolarised 13C imaging

Comparison of acquisition schemes for hyperpolarised 13C imaging
复制标题

DOI:
10.1002/nbm.3301
复制
发表时间:
2015-06-01
期刊:
影响因子:
2.9
通讯作者:
Schulte, Rolf F.
Schulte, Rolf F.
中科院分区:
医学3区
文献类型:
--
作者:
Durst, Markus;Koellisch, Ulrich;Schulte, Rolf F.

文献摘要

被引文献

相似文献

本研究的目的是描述和比较广泛使用的超偏振C-13成像采集策略。设计了自由感应衰变化学位移成像(FIDCSI)、回波平面光谱成像(EPSI)、IDEAL螺旋化学位移成像(ISPCSI)和螺旋化学位移成像(SPCSI)序列,用于两种不同的空间分辨率。在临床3-T扫描仪上注射超极化[1-C-13]丙酮酸后,在模拟和荷瘤大鼠中研究了它们的特征。在同一只大鼠身上随机使用两种或三种不同的序列进行直接比较。实验得到的肿瘤中乳酸的信噪比(SNR)与模拟结果相符。序列间的差异主要体现在编码效率、梯度需求和伪影行为等方面。尽管ISPCSI和SPCSI提供了很高的编码效率,但这些非笛卡尔轨迹比EPSI和FIDCSI更容易受到来自各种来源的伪像的影响。如果编码效率足以满足所需的应用,EPSI已被证明是一个稳健的选择。否则,建议采用更快的螺旋采集方案。本研究的结论可直接应用于临床。版权所有:John Wiley & Sons, Ltd
The aim of this study was to characterise and compare widely used acquisition strategies for hyperpolarised C-13 imaging. Free induction decay chemical shift imaging (FIDCSI), echo-planar spectroscopic imaging (EPSI), IDEAL spiral chemical shift imaging (ISPCSI) and spiral chemical shift imaging (SPCSI) sequences were designed for two different regimes of spatial resolution. Their characteristics were studied in simulations and in tumour-bearing rats after injection of hyperpolarised [1-C-13]pyruvate on a clinical 3-T scanner. Two or three different sequences were used on the same rat in random order for direct comparison. The experimentally obtained lactate signal-to-noise ratio (SNR) in the tumour matched the simulations. Differences between the sequences were mainly found in the encoding efficiency, gradient demand and artefact behaviour. Although ISPCSI and SPCSI offer high encoding efficiencies, these non-Cartesian trajectories are more prone than EPSI and FIDCSI to artefacts from various sources. If the encoding efficiency is sufficient for the desired application, EPSI has been proven to be a robust choice. Otherwise, faster spiral acquisition schemes are recommended. The conclusions found in this work can be applied directly to clinical applications. Copyright (c) 2015 John Wiley & Sons, Ltd.